MGI PHARMA UNVEILS DACOGEN (DECITABINE) FOR INJECTION.
"In line with our strategy, MGI PHARMA continues to expand its presence in oncology and acute care. The introduction of Dacogen is a significant step in our penetration of these markets and in our path to generating $1 billion in total revenue by 2010. In addition to Dacogen, MGI PHARMA markets Aloxi and Gliadel, and has five ongoing pivotal programs to drive future growth," said Lonnie Moulder, president and CEO of MGI PHARMA. "With our field commercial organization now trained, we look forward to discussing the availability of Dacogen with the hematologists and oncologists who treat patients with MDS."
Results from a phase 3 clinical trial of Dacogen demonstrated an overall response rate of 21% in Dacogen-treated patients considered evaluable for response, defined as those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment, compared to 0% in the supportive care arm. All patients who responded to Dacogen treatment became or remained transfusion independent during the time of the response. It is recommended that patients be treated with Dacogen for a minimum of four cycles, and treatment may continue as long as the patient continues to benefit.
Important Safety Information
Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards.
The most commonly occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Visit http://www.mgipharma.com for full prescribing information.
Ongoing Clinical Studies
MGI PHARMA is currently conducting a phase 3 pivotal trial to evaluate Dacogen in patients with AML. Additional phase 2 studies are also underway to evaluate alternative dosing regimens for Dacogen in patients with MDS, AML and chronic myelogenous leukemia, or CML. A phase 3 European Organization for Research and Treatment of Cancer- (EORTC-) sponsored study of Dacogen in patients with MDS is ongoing in Europe.
Myelodysplastic syndromes, or MDS, are a group of diseases of the bone marrow characterized by the production of poorly functioning and immature blood cells. People with MDS may experience a variety of symptoms and complications, including anemia, bleeding, infection, fatigue and weakness. Those patients with high-risk MDS may experience bone marrow failure, which may lead to death from bleeding and infection. Over time, MDS can progress to acute leukemia, or AML. The Aplastic Anemia and MDS International Foundation currently estimates that up to 30,000 new cases of MDS are diagnosed annually in the United States.
About Dacogen(tm) (Decitabine)For Injection
Dacogen is a hypomethylating agent that is believed to exert its antineoplastic effects by incorporation into DNA and inhibition of an enzyme called DNA methyltransferase. Methylation is a process in which methyl (CH3) groups are added to DNA, resulting in the inactivation of genes that are critical for control of cellular differentiation and proliferation. Abnormal methylation, which silences certain genes, is associated with the development of many types of tumors. Dacogen-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of Dacogen may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to Dacogen.
About MGI PHARMA
MGI PHARMA, INC. is an oncology- and acute care-focused biopharmaceutical company that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leading biopharmaceutical company. MGI PHARMA markets Aloxi(r) (palonosetron hydrochloride) Injection, Dacogen(tm) (decitabine) for Injection and Gliadel (r) Wafer (polifeprosan 20 with carmustine implant) in the United States. The company directly markets its products in the U.S. and collaborates with partners to reach international markets.
For more information, visit http://www.mgipharma.com or http://www.dacogen.com or call 212/332-4381.
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 1, 2006|
|Previous Article:||VIOQUEST INITIATES CLINICAL TRIAL FOR AKT THERAPEUTIC.|
|Next Article:||CEPTYR BEGINS IND-ENABLING STUDIES FOR TYPE II DIABETES.|
|MGI PHARMA EXPECTS $78 MILLION TOTAL REVENUE FOR FIRST QTR.|
|MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2 MIL.|
|FDA approves MGI PHARMA, SuperGen's Dacogen as new treatment for myelodysplastic syndromes.|